-
Mashup Score: 11Availability of quality-of-life results for clinical decisions: an evolving scenario - 4 month(s) ago
Attention to patient-reported outcomes and health-related quality of life (QoL) as an endpoint in clinical trials in oncology is constantly rising.1 In principle, data collected, analysed and presented within clinical trials have both scientific and regulatory implications.2 Although recently defined a ‘Cinderella’ outcome,3 the availability of QoL results can contribute to the definition of treatment value4 and can inform communication with patients.5
Source: bmjoncology.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis - 4 month(s) ago
Background Mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) occur in a subset of cancers and have been shown to confer sensitivity to immune checkpoint inhibition (ICI); however, there is a lack of prospective data in urothelial carcinoma (UC).Methods and analysis We performed a systematic review to estimate the prevalence of dMMR and MSI-H in UC, including survival and clinical outcomes. We searched for studies published up to 26 October 2022 in major scientific databases. We screened 1745 studies and included 110. Meta-analyses were performed if the extracted data were suitable.Results The pooled weighted prevalences of dMMR in bladder cancer (BC) and upper tract UC (UTUC) were 2.30% (95% CI 1.12% to 4.65%) and 8.95% (95% CI 6.81% to 11.67%), respectively. The pooled weighted prevalences of MSI-H in BC and UTUC were 2.11% (95% CI 0.82% to 5.31%) and 8.36% (95% CI 5.50% to 12.53%), respectively. Comparing localised versus metastatic disease, the pooled wei
Source: bmjoncology.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Addressing the hidden toxicities of cancer: a call to action for clinicians, researchers and clinical trialists - 5 month(s) ago
The impact of adverse events on patient adherence to cancer treatments is well documented. Most relationships of interest to the clinician focus on biochemical interactions between the patient, treatment and tumour. Yet these events and outcomes are a subset of cancer and cancer treatment toxicity. Patients, caregivers, family and friends navigate treacherous waters behind the scenes to overcome hidden toxicities.
Source: bmjoncology.bmj.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 4
Research is fundamental for effective cancer treatment to improve patient outcomes worldwide. On one hand, research has driven innovation and delivered treatments that have changed clinical practice for the better. On the other hand, lies concerning disparities. Previous literature outlines the
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 25Sex and authorship in global cancer research - 6 month(s) ago
Introduction Research is an essential pillar of cancer control and key in shaping regional cancer control agendas. Imbalances in science and technology in terms of lack of female participation have been well documented. However, there is little evidence about country-level female participation in cancer research. Methodology Through a complex filter, cancer research papers were identified and grouped by countries and sex of the first and last authors of each paper and analysed by the percentage of females in these positions alongside other parameters. Results Our analysis of 56 countries’ outputs, in 2009, revealed that females were the first authors in 37.2% and last authors in 23.3% of papers. In 2019, females were the first author in 41.6% and last author in 29.4% of papers. Females increased as first authors by 26%, and as last authors by 12% between these two time periods. The top performing countries in terms female/male parity for first or last authorship were in Eastern and Sou
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
Research is fundamental for effective cancer treatment to improve patient outcomes worldwide. On one hand, research has driven innovation and delivered treatments that have changed clinical practice for the better. On the other hand, lies concerning disparities. Previous literature outlines the
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 25Sex and authorship in global cancer research - 6 month(s) ago
Introduction Research is an essential pillar of cancer control and key in shaping regional cancer control agendas. Imbalances in science and technology in terms of lack of female participation have been well documented. However, there is little evidence about country-level female participation in cancer research. Methodology Through a complex filter, cancer research papers were identified and grouped by countries and sex of the first and last authors of each paper and analysed by the percentage of females in these positions alongside other parameters. Results Our analysis of 56 countries’ outputs, in 2009, revealed that females were the first authors in 37.2% and last authors in 23.3% of papers. In 2019, females were the first author in 41.6% and last author in 29.4% of papers. Females increased as first authors by 26%, and as last authors by 12% between these two time periods. The top performing countries in terms female/male parity for first or last authorship were in Eastern and Sou
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Nanomedicine in Oncology | BMJ Oncology - 8 month(s) ago
Submi ssion Open: 2nd October 2023 Submission Deadline: 29th March 2024 We are pleased to offer a 25% discount on the Article Processing Charge (APC) for articles submitted to this Topic Collection. Please visit our author hub for more information about the benefits of submitting to a Topic Collection. In the past few decades, significant progress has been made in the treatment and diagnosis of tumours. However, side effects, drug resistance and early-stage diagnosis remain challenges that will dampen
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Nanomedicine in Oncology | BMJ Oncology - 8 month(s) ago
Submi ssion Open: 2nd October 2023 Submission Deadline: 29th March 2024 We are pleased to offer a 25% discount on the Article Processing Charge (APC) for articles submitted to this Topic Collection. Please visit our author hub for more information about the benefits of submitting to a Topic Collection. In the past few decades, significant progress has been made in the treatment and diagnosis of tumours. However, side effects, drug resistance and early-stage diagnosis remain challenges that will dampen
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Nanomedicine in Oncology | BMJ Oncology - 9 month(s) ago
Submi ssion Open: 2nd October 2023 Submission Deadline: 29th March 2024 We are pleased to offer a 25% discount on the Article Processing Charge (APC) for articles submitted to this Topic Collection. Please visit our author hub for more information about the benefits of submitting to a Topic Collection. In the past few decades, significant progress has been made in the treatment and diagnosis of tumours. However, side effects, drug resistance and early-stage diagnosis remain challenges that will dampen
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
Availability of quality-of-life results for clinical decisions: an evolving scenario https://t.co/Z8ZOBNDK8u via @MassimoDiMaio75